Stryker clears Sonopet 3. BTIG cuts target for Stryker stock to USD 316

Published on 10/16/2026 at 10:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 6.59 billion, up 9.40 percent year over year. Stryker stock costs EUR 261.05 on October 16, 2026, 0.10 percent above Xetra close.

Product launch and earnings context

Stryker received FDA 510(k) clearance for Sonopet 3 on October 14, 2026.
Second-quarter revenue was USD 6.59 billion, up 9.40 percent year over year.
Stryker stock trades at EUR 261.05 at 10:32 a.m. CEST at Lang & Schwarz on October 16, 2026, 0.10 percent above the Xetra close of October 15, 2026.

Flatlay mit Aktienzertifikat, ISIN-Karte, Stethoskop und orthopädischem Implantatmodell — Flatlay-Arrangement mit Aktienzertifikat und ISIN-Karte US8636671013 illustriert eine Investition in Stryker Corp. Medizintechnik-Aktien, Illustration mit AI erstellt.

Stryker Corporation (ISIN US8636671013) was trading at EUR 261.05 at Lang & Schwarz on October 16, 2026, at 10:32 a.m. CEST, 0.10 percent above the Xetra close of October 15, 2026, at EUR 260.80. The latest company event was FDA clearance for Sonopet 3, a new ultrasonic tissue removal platform, on October 14, 2026, as Stryker reported.

Sonopet 3 expands the product range

The 510(k) clearance covers the latest version of Stryker's ultrasonic bone and soft tissue removal platform. The company said on October 14, 2026, that Sonopet 3 adds RISE and Pulse Control technologies and was developed with input from hundreds of surgeons, according to Stryker. Initial clinical cases are expected in October, with a broader commercial launch planned for later in the fall.

What does the earnings base show?

Stryker reported second-quarter 2026 revenue of USD 6.59 billion on July 30, 2026, up 9.40 percent year over year, while adjusted earnings per share reached USD 3.69 against a USD 3.49 consensus estimate, according to MarketBeat. The comparison matters because the next report will show whether the growth rate held against the prior year's stronger base.

Three dated signals shape the story

On July 30, 2026, Stryker reported USD 6.59 billion in second-quarter revenue. On October 12, 2026, BTIG Research cut its price target from USD 358.00 to USD 316.00 while keeping a Buy rating, as reported by Markets Insider. On October 14, 2026, Stryker received the Sonopet 3 clearance.

Two dates are next

Stryker will discuss third-quarter 2026 results on October 29, 2026, at 4:30 p.m. ET, according to BioSpace. The company is scheduled to pay a quarterly dividend of USD 0.88 on October 30, 2026, according to MarketBeat.

Stock valuation remains event-driven

The primary-market 52-week range was USD 267.00 to USD 392.55 as of October 15, 2026, while market capitalization stood at USD 112.5 billion. The euro quote was 0.10 percent above the Xetra close, leaving the product launch and the October earnings date as the clearest near-term reference points. Stryker was trading at EUR 261.05 at Lang & Schwarz on October 16, 2026, at 10:32 a.m. CEST, 0.10 percent above the Xetra close of October 15, 2026, at EUR 260.80. The further course of trading is shown by the continuously updated real-time quote of Stryker stock.